Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Seoul National University Hospital |
---|---|
Information provided by: | Seoul National University Hospital |
ClinicalTrials.gov Identifier: | NCT00723060 |
OBJECTIVE: The objective of this study is to compare the effect and safety of conventional dose (20mg) and high dose (40mg) of escitalopram in patients with obsessive-compulsive disorder (OCD).
OVERVIEW OF STUDY DESIGN: Prospective, Randomized, Active-controlled, Double-blind, Multi-center, Clinical Trials STUDY POPULATION: Patients with OCD EFFICACY EVALUATIONS: Y-BOCS (D-YBOCS), HAM-D, HAM-A, CGI-S & -I, GAF, OCI-R SAFETY EVALUATION: Adverse Events / Serious Adverse Events, UKU
Condition | Intervention | Phase |
---|---|---|
Obsessive Compulsive Disorder |
Drug: escitalopram |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment |
Official Title: | Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-Compulsive Disorder (Randomized, Double-Blind, Multi-Center Study) |
Estimated Enrollment: | 166 |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
escitalopram high dose group
|
Drug: escitalopram
escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
|
2: Active Comparator
escitalopram conventional group
|
Drug: escitalopram
escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jun Soo Kwon, M.D., Ph.D. | kwonjs@snu.ac.kr |
Korea, Republic of | |
Seoul National University Hospital | |
Seoul, Korea, Republic of, 110-744 |
Principal Investigator: | Jun Soo Kwon, M.D., Ph.D. | Seoul National University Hospital, Seoul, Korea |
Responsible Party: | Seoul National University Hospital ( Seoul National University Hospital ) |
Study ID Numbers: | 11769A |
Study First Received: | July 24, 2008 |
Last Updated: | July 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00723060 |
Health Authority: | Korea: Food and Drug Administration |
Anxiety Disorders Mental Disorders Dexetimide |
Citalopram Serotonin Obsessive-Compulsive Disorder |
Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Cholinergic Antagonists Anti-Dyskinesia Agents Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Cholinergic Agents |
Serotonin Uptake Inhibitors Pharmacologic Actions Muscarinic Antagonists Serotonin Agents Pathologic Processes Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |